Mon, Apr 28, 9:22 PM (19 days ago)
### Summary of Nutriband Inc. (NTRB) Annual Report **Financial Performance:** - **Revenue:** $2,139,537 (2025) vs. $2,085,314 (2024) - **Net Loss:** $10,482,617 (2025) vs. $5,485,314 (2024) - **Earnings per Share (EPS):** $(0.99) (2025) vs. $(0.69) (2024) **Operating Expenses:** - **Cost of Revenue:** $1,396,220 (2025) vs. $1,223,209 (2024) - **Selling, General, and Administrative Expenses:** $4,313,810 (2025) vs. $3,773,606 (2024) - **Research and Development:** $3,119,134 (2025) vs. $1,960,425 (2024) - **Goodwill and Intangibles Impairment:** $3,595,216 (2025) **Cash Flow:** - **Operating Cash Flow:** $(4,626,564) (2025) vs. $(3,527,509) (2024) - **Investing Cash Flow:** $(92,043) (2025) vs. $(51,761) (2024) - **Financing Cash Flow:** $8,537,384 (2025) vs. $2,086,772 (2024) **Strategic Overview:** - **Core Business:** Development of transdermal pharmaceutical products, focusing on abuse-deterrent technologies. - **Lead Product:** AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system. - **Market Position:** AVERSA Fentanyl aims to be the first fentanyl transdermal system with abuse-deterrent properties. **Future Outlook:** - **Market Potential:** AVERSA Fentanyl has a potential peak annual US sales of $80-200 million. - **Development Pipeline:** Includes AVERSA Buprenorphine and AVERSA Methylphenidate. - **Regulatory Pathway:** Plans to use the 505(b)(2) NDA regulatory pathway for AVERSA Fentanyl. **Risk Factors:** - **Regulatory Risks:** Dependence on FDA approval and compliance with regulatory requirements. - **Financial Risks:** High operating losses and reliance on equity financing. - **Market Risks:** Competition and potential changes in opioid prescribing guidelines. **Financial Condition:** - **Cash and Cash Equivalents:** $4,311,719 (2025) vs. $492,942 (2024) - **Working Capital:** $3,811,420 (2025) vs. $22,770 (2024) **Market Position Changes:** - **Equity Financing:** Completed an $8,400,000 equity financing in 2024. - **Stock Performance:** Volatile stock price with low trading volume. **Other Notable Points:** - **Legal Proceedings:** Ongoing lawsuit with Joseph Gunnar, LLC and Lucosky Brookman LLP. - **Intellectual Property:** Strong patent portfolio covering AVERSA technology in multiple countries. - **Corporate Governance:** Board of Directors includes a mix of independent and executive directors.